Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CHRS with free AI briefings, catalyst countdowns, and dilution alerts.

CHRS · Coherus Oncology, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$136M Cash on Hand
8.5mo Cash Runway
Follow CHRS by email Get an email when CHRS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CHRS, unsubscribe in one click. Privacy

📣 What CHRS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Toripalimab
FDA approved Oct 2023 · Loqtorzi
Nasopharyngeal Cancer Recurrent Phase 4 · NCT06457503 Recruiting
CHS-1420 Plaque Psoriasis Phase 3 · NCT02489227 Completed
CHS-0214 Plaque Psoriasis Phase 3 · NCT02134210 Completed
NY-ESO-1 Peptide Vaccine Ovarian Cancer Stage IV Phase 2 · NCT05479045 Withdrawn
Zimberelimab Metastatic Castration-resistant Prostate Cancer Phase 2 · NCT05177770 Terminated
METTL-3 Inhibitor STC-15 Solid Tumor Phase 1/2 · NCT06975293 Recruiting
Perenostobart (SRF617) Metastatic Castration-resistant Prostate Cancer Phase 2 · NCT05177770 Terminated
Nidanilimab Metastatic Microsatellite Stable Colorectal Carcinoma Phase 1/2 · NCT07281716 Recruiting
Etrumadenant Metastatic Castration-resistant Prostate Cancer Phase 2 · NCT05177770 Terminated
Casdozokitug (CHS-388) Hepatocellular Carcinoma Phase 2 · NCT06679985 Active not recruiting
Anti-TIGIT Monoclonal Antibody TAB006 Advanced Solid Tumor Phase 1 · NCT05757492 Terminated
CHS-1701 Healthy Phase 1 · NCT02650973 Completed
Nab-paclitaxel Advanced Solid Tumor Phase 1 · NCT04336098 Completed
Fluorouracil Metastatic Solid Tumor Phase 1 · NCT06657144 Recruiting
Tagmokitug (CHS-114) Metastatic Solid Tumor Phase 1 · NCT06657144 Recruiting
Anti-ILT4 Monoclonal Antibody CHS-1000 Advanced or Metastatic Solid Tumors Phase 1 · NCT06389526 Not yet recruiting

Also used in these trials (approved or third-party drugs, not CHRS's own candidates): Gemcitabine Hydrochloride, Cisplatin, Carboplatin, Adalimumab, Etanercept, Paclitaxel, Dupilumab, Bevacizumab, Docetaxel Anhydrous, Atezolizumab, Pegfilgrastim, Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CHRS holds $136M in cash and short-term investments (as of Sep 30, 2026) and burns about $48.1M/quarter from operations, an estimated runway of 8.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 84 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CHRS files for a raise →

👥 Who Owns CHRS

Insiders 1.3% Other 5%+ holders 8.3% Institutions (184 holders) 35.8% Public and other holders 54.6%
HolderTypeShares% of sharesAs of
Timothy G. Youngquist 2020 Irrevocable T 5%+ holder (13G) 12,750,800 8.25% 2026-03-31
BlackRock, Inc. Institution (13G, 5%+) 8,934,952 5.78% 2026-06-30
Dennis M Lanfear
President & CEO, Director · +2.12M options
Insider 1,567,884 1.01% 2026-01-23
Bryan J McMichael
Chief Financial Officer · +690,000 options
Insider 133,736 0.09% 2026-01-22
Paul Reider
Chief Commercial Officer · +200,000 options
Insider 82,069 0.05% 2025-01-20
Lee Nisley Newcomer
Director · +172,000 options
Insider 30,000 0.02% 2026-06-05
Michael Lee Ryan
Director · +172,000 options
Insider 30,000 0.02% 2026-06-05
Jill O'Donnell-Tormey
Director · +172,000 options
Insider 30,000 0.02% 2026-06-05
Charles W. Newton
Director · +284,000 options
Insider 30,000 0.02% 2026-06-05
Ali J. Satvat
Director · +172,000 options
Insider 30,000 0.02% 2026-06-05
Rita A Karachun
Director · +340,000 options
Insider 30,000 0.02% 2026-06-05
Mats Wahlstrom
Director · +172,000 options
Insider 30,000 0.02% 2026-06-05

Share count 154,538,277 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CHRS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CHRS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.